Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

Johnson & Johnson submits sNDA to US FDA for Caplyta for prevention of relapse in schizophrenia: Titusville, New Jersey Wednesday, July 9, 2025, 14:00 Hrs [IST] Johnson & Johnson ...

I am a passive income investor. I make my money work for me and get more money to invest. This way, I can supplement my ...

A 49-study meta-analysis showed that the mean number of discontinuation symptoms 1 week after stopping an antidepressant was ...

A U.S. appeals court has sided with Johnson & Johnson (NYSE:JNJ) in a patent dispute with Viatris (NASDAQ:VTRS) and Teva ...